GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » Cyclically Adjusted PB Ratio

Check-Cap (Check-Cap) Cyclically Adjusted PB Ratio : 0.03 (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Check-Cap Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Check-Cap's current share price is $2.22. Check-Cap's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $87.27. Check-Cap's Cyclically Adjusted PB Ratio for today is 0.03.

The historical rank and industry rank for Check-Cap's Cyclically Adjusted PB Ratio or its related term are showing as below:

CHEK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.05
Current: 0.03

During the past years, Check-Cap's highest Cyclically Adjusted PB Ratio was 0.05. The lowest was 0.00. And the median was 0.00.

CHEK's Cyclically Adjusted PB Ratio is ranked better than
96.97% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96 vs CHEK: 0.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Check-Cap's adjusted book value per share data for the three months ended in Sep. 2023 was $4.683. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $87.27 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Check-Cap Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Check-Cap's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap Cyclically Adjusted PB Ratio Chart

Check-Cap Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Check-Cap Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.02 0.03 0.05

Competitive Comparison of Check-Cap's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Check-Cap's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Check-Cap's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Check-Cap's Cyclically Adjusted PB Ratio falls into.



Check-Cap Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Check-Cap's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.22/87.27
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Check-Cap's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Check-Cap's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=4.683/129.8595*129.8595
=4.683

Current CPI (Sep. 2023) = 129.8595.

Check-Cap Quarterly Data

Book Value per Share CPI Adj_Book
201312 38.600 98.326 50.979
201403 0.000 99.695 0.000
201406 -48.960 100.560 -63.225
201409 0.000 100.428 0.000
201412 -21.193 99.070 -27.780
201503 377.077 99.621 491.533
201506 201.735 100.684 260.193
201509 211.040 100.392 272.987
201512 255.103 99.792 331.965
201603 203.581 100.470 263.131
201606 170.682 101.688 217.967
201609 222.309 101.861 283.415
201612 164.278 101.863 209.430
201703 122.543 102.862 154.706
201706 107.873 103.349 135.544
201709 78.536 104.136 97.936
201712 73.564 104.011 91.846
201803 41.578 105.290 51.281
201806 70.008 106.317 85.511
201809 59.800 106.507 72.912
201812 48.906 105.998 59.915
201903 40.047 107.251 48.489
201906 32.332 108.070 38.851
201909 24.082 108.329 28.868
201912 15.071 108.420 18.051
202003 13.922 108.902 16.601
202006 9.944 108.767 11.872
202009 8.737 109.815 10.332
202012 7.084 109.897 8.371
202103 9.112 111.754 10.588
202106 8.017 114.631 9.082
202109 11.605 115.734 13.021
202112 10.515 117.630 11.608
202203 9.270 121.301 9.924
202206 8.491 125.017 8.820
202209 7.714 125.227 7.999
202212 7.069 125.222 7.331
202303 6.331 127.348 6.456
202306 5.161 128.729 5.206
202309 4.683 129.860 4.683

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Check-Cap  (NAS:CHEK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Check-Cap Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Check-Cap's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Check-Cap (Check-Cap) Business Description

Traded in Other Exchanges
Address
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.